President Donald Trump announced the nomination of Dr. Heidi Overton to serve as commissioner of the Food and Drug Administration on Wednesday. Overton, who holds a medical degree from the University of New Mexico and a doctoral degree in clinical investigation from Johns Hopkins University, currently serves as deputy director of the White House Domestic Policy Council. She previously worked as chief policy officer at the America First Policy Institute, a conservative think tank.
Trump characterized Overton as a “rockstar” who would advance his administration’s priorities including faster drug development, innovation, lower medication costs and support for Health and Human Services Secretary Robert F. Kennedy Jr.’s “Make America Healthy Again” initiative. Kennedy praised Overton’s “exceptional judgment, professionalism, discipline and an unwavering commitment to the American people.” In recent months, Overton has participated in announcing major administration health initiatives, including drug pricing negotiations and a vaccine order.
If confirmed by the Senate, Overton would assume leadership of an agency facing multiple competing demands. Her tenure would follow that of Dr. Marty Makary, who resigned in May, leaving unfinished work on ultraprocessed foods, antidepressants and COVID-19 vaccines. The FDA has also faced industry pressure regarding drug approvals for rare diseases and electronic cigarette regulation.
Overton’s nomination faces potential obstacles in the narrowly Republican-led Senate. Sen. Bill Cassidy, a Louisiana physician and chair of the Senate Health, Education, Labor and Pensions Committee, posted Wednesday that while he respects her medical background, he has “strong concerns” about the nomination, citing her lack of managerial experience and participation in the recent vaccine order. Democratic senators opposed the nomination, with Washington Sen. Patty Murray characterizing Overton as “a far-right, anti-abortion extremist” unfit for the position. Abortion opponents have expressed hopes that Overton would roll back FDA rules regarding medication abortion access.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI